Studies have shown that class I HDAC inhibitors (HDACi), specifically chidamide, enhance the persistence and anti-tumor effects of CAR-T cells by upregulating the expression of transcription factors such as LEF1 and TCF4, as well as activating the Wnt/β-catenin pathway [192]. Here, HDAC9 is linked to neoplasm.